Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies.1 Icotrokinra also showed ...
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE ...
Saga plc ( OTCPK:SGPLF) Interim Results Investor Presentation Call ...
The Goldman Sachs U.S. Equity Insights Fund (I-share, net) returned 11.15% in Q2 2025, outperforming the S&P 500 Index by 21 ...
Cyprus has found “sizeable quantities” of natural gas in blocks Pegasus and Glaucus, Energy Minister George Papanastasiou ...
In contrast, the official Ballon d’Or 2025 ranking painted a different picture: after Dembélé, Lamine Yamal took second place, while Portuguese midfielder Vitinha completed the podium. Mohamed Salah ...
Major stock indexes ended mixed Wednesday after the Federal Reserve trimmed interest rates by a quarter percentage point and ...
Photo courtesy of Sri Lanka Brief The NPP government has been in power for a year and it is nearing two years since the ...
We’re praying to outgrow this space,” said Stephanie Reinertsen, a former public high school English teacher who opened Echo ...
SOUTH SAN FRANCISCO, Calif., Sept. 8, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present initial data at their 10-Year ...
Artelo Biosciences (ARTL) announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine cocrystal. The peer-reviewed study, conducted in collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback